![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/aobiome-announces-the-publication-of-positive-phase-2b-results-in-the-lancets-eclinicalmedicine-for-b244-in-the-treatment-of-mild-to-moderate-atopic-dermatitis-and-moderate-to-severe-pruritus-301826082.html
https://www.prnewswire.com/news-releases/aobiome-therapeutics-granted-composition-of-matter-patent-for-its-clinical-candidate-b244-301791237.html
https://www.clinicaltrialsarena.com/news/aobiome-b244-pruritus-eczema/
https://www.prnewswire.com/news-releases/aobiome-achieves-landmark-recruitment-goal-in-largest-clinical-trial-ever-powered-by-a-live-topical-biotherapeutic-301424800.html
https://www.prnewswire.com/news-releases/new-30-patient-study-of-aobiomes-new-shelf-stable-formulation-of-its-ammonia-oxidizing-bacteria-aob-shows-reduction-of-itch-levels-in-both-pediatric-and-adult-subjects-who-suffer-from-eczema-301356425.html